Loading...
Notch inhibition overcomes resistance to tyrosine kinase inhibitors in EGFR-driven lung adenocarcinoma
EGFR-mutated lung adenocarcinoma patients treated with gefitinib and osimertinib show a therapeutic benefit limited by the appearance of secondary mutations, such as EGFR(T790M) and EGFR(C797S). It is generally assumed that these secondary mutations render EGFR completely unresponsive to the inhibit...
Saved in:
| Published in: | J Clin Invest |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
American Society for Clinical Investigation
2019
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6994195/ https://ncbi.nlm.nih.gov/pubmed/31671073 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI126896 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|